Nathan Denlinger

807 total citations
31 papers, 336 citations indexed

About

Nathan Denlinger is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Nathan Denlinger has authored 31 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 6 papers in Immunology. Recurrent topics in Nathan Denlinger's work include CAR-T cell therapy research (19 papers), Lymphoma Diagnosis and Treatment (6 papers) and Acute Myeloid Leukemia Research (3 papers). Nathan Denlinger is often cited by papers focused on CAR-T cell therapy research (19 papers), Lymphoma Diagnosis and Treatment (6 papers) and Acute Myeloid Leukemia Research (3 papers). Nathan Denlinger collaborates with scholars based in United States and United Kingdom. Nathan Denlinger's co-authors include Yiping Yang, Samantha Jaglowski, David A. Bond, Narendranath Epperla, Basem M. William, Adam S. Kittai, Lindsey Fitzgerald, Ying Huang, Agrima Mian and Brian T. Hill and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Endocrinology.

In The Last Decade

Nathan Denlinger

28 papers receiving 333 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nathan Denlinger United States 10 213 111 76 55 50 31 336
Monalisa Ghosh United States 9 170 0.8× 63 0.6× 87 1.1× 46 0.8× 26 0.5× 45 308
Sandra B. Horowitz United States 9 227 1.1× 65 0.6× 77 1.0× 43 0.8× 40 0.8× 14 305
Eugenio Galli Italy 9 176 0.8× 49 0.4× 37 0.5× 43 0.8× 50 1.0× 43 280
Xiaoqian Liang China 6 243 1.1× 98 0.9× 117 1.5× 21 0.4× 68 1.4× 8 334
Diane Baniewicz United States 12 388 1.8× 87 0.8× 91 1.2× 22 0.4× 97 1.9× 16 495
Andy Chen United States 9 206 1.0× 40 0.4× 60 0.8× 114 2.1× 34 0.7× 20 269
Shaun Cordoba United Kingdom 10 232 1.1× 82 0.7× 103 1.4× 53 1.0× 81 1.6× 20 379
Minh Tran United States 6 141 0.7× 69 0.6× 80 1.1× 20 0.4× 36 0.7× 13 259
Alessandro Crotta United States 7 273 1.3× 55 0.5× 48 0.6× 121 2.2× 43 0.9× 26 369
Jiazhen Cui China 11 312 1.5× 118 1.1× 139 1.8× 18 0.3× 76 1.5× 39 423

Countries citing papers authored by Nathan Denlinger

Since Specialization
Citations

This map shows the geographic impact of Nathan Denlinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Denlinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Denlinger more than expected).

Fields of papers citing papers by Nathan Denlinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Denlinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Denlinger. The network helps show where Nathan Denlinger may publish in the future.

Co-authorship network of co-authors of Nathan Denlinger

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Denlinger. A scholar is included among the top collaborators of Nathan Denlinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Denlinger. Nathan Denlinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Qiuhong, Evandro D. Bezerra, Hannah Choe, et al.. (2025). Oral Azacitidine Use after Stem Cell Transplantation for Myeloid Malignancies: A Single Center Experience. Transplantation and Cellular Therapy. 31(2). S429–S430.
2.
Silberman, Pedro C., Yazeed Sawalha, Beth Christian, et al.. (2024). Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 42(16_suppl). 7033–7033. 2 indexed citations
3.
Zhao, Qiuhong, Chenyu Lin, Monalisa Ghosh, et al.. (2024). Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis. Blood Advances. 9(1). 170–175. 12 indexed citations
4.
Denlinger, Nathan, et al.. (2024). Stem-like CD8+ T cells in cancer. Frontiers in Immunology. 15. 1426418–1426418. 6 indexed citations
5.
Zhao, Qiuhong, Timothy Voorhees, Nathan Denlinger, et al.. (2024). Association between post-CART terminal complement complex (TCC) levels and clinically significant immune effector cell–associated neurotoxicity syndrome (ICANS).. Journal of Clinical Oncology. 42(16_suppl). 7036–7036. 1 indexed citations
6.
Voorhees, Timothy, Evandro D. Bezerra, Nathan Denlinger, Samantha Jaglowski, & Marcos de Lima. (2024). SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program. Clinical Lymphoma Myeloma & Leukemia. 24(10). 649–652. 1 indexed citations
7.
Voorhees, Timothy, Ying Huang, Nathan Denlinger, et al.. (2024). Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: Interim Results from a Phase I Clinical Trial. Transplantation and Cellular Therapy. 30(2). S355–S356. 3 indexed citations
8.
Chan, Wing Keung, Jessica Williams, Zehua Bian, et al.. (2023). A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. Experimental Hematology and Oncology. 12(1). 79–79. 9 indexed citations
9.
Zhao, Qiuhong, Agrima Mian, Chenyu Lin, et al.. (2023). Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis. Blood. 142(Supplement 1). 4502–4502. 5 indexed citations
10.
Sigmund, Audrey M., Nathan Denlinger, Ying Huang, et al.. (2022). Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy. 28(6). 342.e1–342.e5. 7 indexed citations
11.
Sigmund, Audrey M., Nathan Denlinger, Patrick Elder, et al.. (2021). Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution. Blood. 138(Supplement 1). 3851–3851. 2 indexed citations
12.
Denlinger, Nathan, David A. Bond, & Samantha Jaglowski. (2021). CAR T-cell therapy for B-cell lymphoma. Current Problems in Cancer. 46(1). 100826–100826. 62 indexed citations
13.
Malik, Saad Ullah, Zachary Braunstein, Sumithira Vasu, et al.. (2021). Cardiac Arrhythmias and Mortality after Hematopoietic Stem Cell Transplant (HSCT): A Systematic Review and Meta-Analysis. Blood. 138(Supplement 1). 2918–2918. 1 indexed citations
14.
Huang, Ying, Rui Li, Nathan Denlinger, et al.. (2021). Prognostic value of early imaging following CAR T-cell therapy in DLBCL.. Journal of Clinical Oncology. 39(15_suppl). e19559–e19559. 2 indexed citations
15.
Kittai, Adam S., Ying Huang, Max J. Gordon, et al.. (2020). Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transplantation and Cellular Therapy. 27(1). 46–52. 37 indexed citations
16.
Denlinger, Nathan, Narendranath Epperla, & Basem M. William. (2018). Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Management and Research. Volume 10. 615–624. 19 indexed citations
17.
Vaughn, John L., David Kline, Nathan Denlinger, Leslie A. Andritsos, & Alison R. Walker. (2016). Performance of Quick Sepsis-Related Organ Failure Assessment (qSOFA) in Predicting Adverse Outcomes in Acute Leukemia Patients Receiving Induction Chemotherapy. Blood. 128(22). 2413–2413. 2 indexed citations
18.
Denlinger, Nathan. (2015). Interstitial Brachytherapy for Locally Advanced Cervical Cancer. 1(1). 1 indexed citations
19.
McCall, Kelly D., Jean Thuma, Marı́a C. Courrèges, et al.. (2014). Toll-Like Receptor 3 Is Critical for Coxsackievirus B4-Induced Type 1 Diabetes in Female NOD Mice. Endocrinology. 156(2). 453–461. 27 indexed citations
20.
Hofmeister, Craig C., et al.. (2007). Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leukemia Research. 32(8). 1295–1298. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monalisa Ghosh Breakdown of academic impact, for papers by Sandra B. Horowitz Breakdown of academic impact, for papers by Eugenio Galli Breakdown of academic impact, for papers by Xiaoqian Liang Breakdown of academic impact, for papers by Diane Baniewicz Breakdown of academic impact, for papers by Andy Chen Breakdown of academic impact, for papers by Shaun Cordoba Breakdown of academic impact, for papers by Minh Tran Breakdown of academic impact, for papers by Alessandro Crotta Breakdown of academic impact, for papers by Jiazhen Cui
Rankless by CCL
2026